


Our History: 25 Years of Linking Innovation to Impact

At Seagen, #WeLink Innovation to Patient Experience




2021

TIVDAK® (tisotumab vedotin-tftv, for injection 40 mg) receives accelerated approval in the U.S. – our fourth approved medicine. Please see full Prescribing Information, including **BOXED WARNING** for Ocular Toxicity.



2019

PADCEV® (enfortumab vedotin-ejfv, for injection 20 mg & 30 mg vials) receives accelerated approval in the U.S. Please see full Prescribing Information, including **BOXED WARNING** for Serious Skin Reactions.



2015

Seagen expands access to ADC technology via collaborations with global technology and pharmaceutical leaders.



2011

ADCETRIS® (brentuximab vedotin, for injection 50 mg) is approved in the U.S. Please see full Prescribing Information, including **BOXED WARNING** for PML.



2006

The first clinical trial patient receives brentuximab vedotin.

2001

Our scientists synthesize monomethyl auristatin E (MMAE), the cytotoxic drug payload for our first investigational antibody–drug conjugate (ADC), brentuximab vedotin.



1998

Seattle Genetics initiates operations in Bothell, Washington, and begins research into anti-CD30 antibodies the following year.

2023

Seagen celebrates its 25th anniversary.

2020

Seattle Genetics, Inc. changes its name to Seagen Inc. to reflect the transformation of the company from its strong Seattle roots into a global operation.



TUKYSA® (tucatinib, 50 mg & 150 mg tablets) is approved in the U.S. and other countries – our third approved and first wholly-owned medicine. Please see full Prescribing Information.

